Percutaneous Closure of Patent Ductus Arteriosus

Clin Perinatol. 2022 Mar;49(1):149-166. doi: 10.1016/j.clp.2021.11.009. Epub 2022 Jan 21.

Abstract

Percutaneous-based patent ductus arteriosus closure is technically feasible among infants less than 1.5 kg. However, marked heterogeneity in the type and nature of adverse events obscures current safety profile assessments. Although data on the risks of postdevice closure syndrome remain promising, a lack of comparative trials of surgical ductal ligation and inconsistent surveillance across published studies obscure confidence in present estimates of safety and efficacy. To minimize risk and yield the greatest benefits, clinical studies of patent ductus arteriosus treatment should consider incorporating more robust assessments to ensure that infants at greatest risk for adverse ductal consequences are included.

Keywords: Catheter-based closure; Patent ductus arteriosus; Percutaneous closure; Preterm infant; Very low birth weight infant.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Ductus Arteriosus, Patent* / surgery
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Ligation
  • Treatment Outcome